Point-of-care diagnostic technology company Lumos Diagnostics (ASX:LDX) states that it has received a purchase order and shipped the product for FebriDx to iMedical.
US company iMedical develops and delivers cost-saving solutions tailored for hospitals, surgery centres, clinics, and healthcare facilities nationwide.
Lumos said the US$126,000 purchase order is the largest received since the launch of FebriDx. FebriDx is a rapid point-of-care respiratory test that delivers results in around 10 minutes from a fingerstick blood sample. In July 2023, the US FDA cleared FebriDx for marketing in the US as an aid in the diagnosis of bacterial acute respiratory infections and in differentiating them from non-bacterial etiologies. The test has been cleared for use by healthcare professionals with patients presenting in urgent care or emergency care settings and is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection.
iMedical CEO Dave Berthold said, “We are excited to partner with Lumos Diagnostics to bring innovative diagnostic solutions to healthcare providers and patients. This collaboration reflects our shared commitment to advancing point-of-care technology and improving health outcomes across the continuum of care."
"I'm pleased to see FebriDx gaining traction and acceptance in the market," said Doug Ward, Lumos CEO and managing director. "It's a testament to the product’s clinical value and growing demand. Lumos looks forward to working more closely with iMedical to expand FebriDx’s market acceptance and adoption."